BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Kanda T, Kato K, Tsubota A, Takada N, Nishino T, Mikami S, Miyamura T, Maruoka D, Wu S, Nakamoto S, Arai M, Fujiwara K, Imazeki F, Yokosuka O. Platelet count and sustained virological response in hepatitis C treatment. World J Hepatol 2013; 5(4): 182-188 [PMID: 23671722 DOI: 10.4254/wjh.v5.i4.182]
URL: https://www.wjgnet.com/1948-5182/full/v5/i4/182.htm
Number Citing Articles
1
Hanan H. Rizk, Nadia M. Hamdy, Nadia L. Al-Ansari, Hala O. El-Mesallamy, Ming-Lung Yu. Pretreatment Predictors of Response to PegIFN-RBV Therapy in Egyptian Patients with HCV Genotype 4PLOS ONE 2016; 11(4): e0153895 doi: 10.1371/journal.pone.0153895
2
Silvia Odolini, Silvia Amadasi, Carlo Cerini, Mariarosaria Giralda, Paola Nasta, Francesco Castelli. Sustained virological response to peginterferon therapy in patients infected with HCV (genotypes 2 and 3), with or without HIVBMC Infectious Diseases 2014; 14(S5) doi: 10.1186/1471-2334-14-S5-S4
3
Ashraf A. Tabll, Mamdouh S. Afifi, Abd-Allah S. El-Etrawy, Salah M. El-Kousy, Martina Smolic, Yasmine S. El Abd. CXCL9 chemokine level is associated with spontaneous clearance and sustained virological response in Egyptian Chronic Hepatitis C patients receiving direct acting antiviralsHuman Antibodies 2020; 28(2): 141 doi: 10.3233/HAB-190400
4
Kanda Tatsuo, Yokosuka Osamu, Omata Masao. Antiviral therapy for “difficult-to-treat” hepatitis C virus-infected patientsChinese Medical Journal 2013; 126(23): 4568 doi: 10.3760/cma.j.issn.0366-6999.20131127
5
Tatsuo Kanda, Shingo Nakamoto, Shuang Wu, Osamu Yokosuka. Role of <italic>IL28B</italic> genotype in older hepatitis C virus-infected patientsWorld Journal of Immunology 2013; 3(3): 54-61 doi: 10.5411/wji.v3.i3.54
6
Baek Gyu Jun, Eui Ju Park, Woong Cheul Lee, Jae Young Jang, Soung Won Jeong, Young Don Kim, Gab Jin Cheon, Young Sin Cho, Sae Hwan Lee, Hong Soo Kim, Yun Nah Lee, Sang Gyune Kim, Young Seok Kim, Boo Sung Kim. Platelet count is associated with sustained virological response rates in treatments for chronic hepatitis CThe Korean Journal of Internal Medicine 2019; 34(5): 989 doi: 10.3904/kjim.2017.322
7
Samar Kamal Darweesh. Pathology Predictors of Response to Combined Therapy of Chronic HCV Patients; Is it Applicable in the DAA Era?Gastroenterology & Hepatology: Open Access 2016; 5(8) doi: 10.15406/ghoa.2016.05.00176
8
Rabab Fouad, Khaled Zachariah, Marwa Khairy, Mervat Khorshied, Wafaa Ezzat, Marwa M. Sheta, Ahmed Heiba. Single Nucleotiders760370Polymorphism at the Main Ribavirin Transporter Gene Detection by PCR-RFLP Assay Compared with the TaqMan Assay and Its Relation to Sustained Virological Response in Chronic HCV Patients Treated with Pegylated Interferon–Ribavirin TherapyJournal of Interferon & Cytokine Research 2017; 37(2): 90 doi: 10.1089/jir.2016.0099
9
J. M. Boone, W. Cui. Spectrum of bone marrow morphologic findings in hepatitis C patients with and without prior liver transplantationInternational Journal of Laboratory Hematology 2016; 38(6): 694 doi: 10.1111/ijlh.12559